loader
Please Wait
Applying Filters...

Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Orkambi, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Orkambi

    GLOBAL SALES INFORMATION

    MARKET PLACE

    DIGITAL CONTENT

    PharmaCompass

    Inke S.A: APIs manufacturing plant.

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    2D Structure
    1. Also known as: Lumacaftor / ivacaftor, Lumacaftor and ivacaftor, Lumacaftor and ivacaftor tablet, Schembl19410545, Vx 700-vx 809 combination, Vx 809-vx 770 combination
    Molecular Formula
    C48H46F2N4O8
    Molecular Weight
    844.9  g/mol
    InChI Key
    YQCGOSZYHRVOFW-UHFFFAOYSA-N
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide;3-[6-[[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino]-3-methylpyridin-2-yl]benzoic acid
    2.1.2 InChI
    InChI=1S/C24H18F2N2O5.C24H28N2O3/c1-13-5-8-19(27-20(13)14-3-2-4-15(11-14)21(29)30)28-22(31)23(9-10-23)16-6-7-17-18(12-16)33-24(25,26)32-17;1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h2-8,11-12H,9-10H2,1H3,(H,29,30)(H,27,28,31);7-13,27H,1-6H3,(H,25,28)(H,26,29)
    2.1.3 InChI Key
    YQCGOSZYHRVOFW-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    CC1=C(N=C(C=C1)NC(=O)C2(CC2)C3=CC4=C(C=C3)OC(O4)(F)F)C5=CC(=CC=C5)C(=O)O.CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C
    2.2 Synonyms
    2.2.1 MeSH Synonyms

    1. Ivacaftor - Lumacaftor

    2. Ivacaftor, Lumacaftor Drug Combination

    3. Lumacaftor, Ivacaftor Drug Combination

    2.2.2 Depositor-Supplied Synonyms

    1. Lumacaftor / Ivacaftor

    2. Lumacaftor And Ivacaftor

    3. Lumacaftor And Ivacaftor Tablet

    4. Schembl19410545

    5. Vx 700-vx 809 Combination

    6. Vx 809-vx 770 Combination

    7. Ivacaftor Mixture With Lumacaftor

    8. Lumacaftor, Ivacaftor Drug Combination

    9. S900006790

    10. 1815566-23-4

    2.3 Create Date
    2013-06-10
    3 Chemical and Physical Properties
    Molecular Weight 844.9 g/mol
    Molecular Formula C48H46F2N4O8
    Hydrogen Bond Donor Count5
    Hydrogen Bond Acceptor Count12
    Rotatable Bond Count9
    Exact Mass844.32837076 g/mol
    Monoisotopic Mass844.32837076 g/mol
    Topological Polar Surface Area176 Ų
    Heavy Atom Count62
    Formal Charge0
    Complexity1450
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 1  
    Drug NameORKAMBI
    Active IngredientIVACAFTOR; LUMACAFTOR
    CompanyVERTEX PHARMS INC (Application Number: N206038. Patents: 7495103, 7973038, 8324242, 8410274, 8507534, 8653103, 8716338, 8741933, 8754224, 8846718, 8993600, 9150552, 9192606, 9216969, 9670163, 9931334)

    4.2 Drug Indication

    Orkambi tablets are indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation in the CFTR gene.

    Orkambi granules are indicated for the treatment of cystic fibrosis (CF) in children aged 2 years and older who are homozygous for the F508del mutation in the CFTR gene.

    5 Pharmacology and Biochemistry
    5.1 FDA Pharmacological Classification
    5.1.1 Pharmacological Classes
    Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]; Cytochrome P450 2B6 Inducers [MoA]; Cytochrome P450 2C19 Inducers [MoA]; Cytochrome P450 2C8 Inducers [MoA]; Cytochrome P450 2C8 Inhibitors [MoA]; Cytochrome P450 2C9 Inducers [MoA]; Cytochrome P450 2C9 Inhibitors [MoA]; Cytochrome P450 3A Inducers [MoA]; Cytochrome P450 3A Inhibitors [MoA]; P-Glycoprotein Inducers [MoA]; P-Glycoprotein Inhibitors [MoA]; Chloride Channel Activation Potentiators [MoA]
    5.2 ATC Code

    R07AX30

    Post Enquiry
    POST ENQUIRY